Thermo Fisher nears $10 bln deal to acquire Clario, FT reports By Investing.com
Update: 2025-10-29
Description
Thermo Fisher Scientific is on the brink of acquiring Clario, a leading drug trial software company, for approximately ten billion dollars. This deal, if finalized, would provide Thermo Fisher with Clario's robust digital platform used in over twenty-six thousand trials across one hundred countries, generating around four hundred million dollars in adjusted earnings annually. The acquisition would significantly enhance Thermo Fisher's offerings to global drug developers, particularly as digitizing drug trials becomes increasingly important. If successful, this deal would be one of the year's largest private equity exits and could set a new precedent for future life sciences and tech company mergers.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
